Review
doi: 10.1016/j.molmed.2003.12.005.
Altered states: selectively drugging the Hsp90 cancer chaperone
Affiliations
- PMID: 15106614
- DOI: 10.1016/j.molmed.2003.12.005
Item in Clipboard
Review
Altered states: selectively drugging the Hsp90 cancer chaperone
Trends Mol Med.
2004 Feb.
Abstract
The molecular chaperone Hsp90 is an exciting cancer drug target. The first Hsp90 inhibitor to enter clinical trials--the geldanamycin derivative 17AAG--has recently demonstrated proof-of-concept for successful target modulation, with sighs of therapeutic benefit. An important property of Hsp90 inhibitors is their ability to cause simultaneous, combinatorial blockade of multiple cancer-causing pathways by promoting the degradation of many oncogenic client proteins. However, the reason for therapeutic selectivity in cancer cells versus normal cells is unclear. New research now shows that Hsp90 exists in cancer cells in a heightened, activated state that is highly susceptible to inhibition by 17AAG.
Similar articles
-
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.J Natl Cancer Inst. 1999 Nov 17;91(22):1940-9. doi: 10.1093/jnci/91.22.1940. J Natl Cancer Inst. 1999. PMID: 10564678
-
Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.Clin Cancer Res. 2000 Aug;6(8):3312-8. Clin Cancer Res. 2000. PMID: 10955818
-
[Molecular chaperone HSP90 as a novel target for cancer chemotherapy].Nihon Yakurigaku Zasshi. 2003 Jan;121(1):33-42. doi: 10.1254/fpj.121.33. Nihon Yakurigaku Zasshi. 2003. PMID: 12617036 Review. Japanese.
-
Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin.J Med Chem. 1999 Jan 28;42(2):260-6. doi: 10.1021/jm980403y. J Med Chem. 1999. PMID: 9925731
-
Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.Curr Med Chem. 2003 May;10(9):733-9. doi: 10.2174/0929867033457818. Curr Med Chem. 2003. PMID: 12678776 Review.
Cited by
-
Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening.PLoS One. 2013;8(4):e59315. doi: 10.1371/journal.pone.0059315. Epub 2013 Apr 2. PLoS One. 2013. PMID: 23565147 Free PMC article.
-
Large-Scale Analysis of Breast Cancer-Related Conformational Changes in Proteins Using Limited Proteolysis.J Proteome Res. 2016 Dec 2;15(12):4666-4674. doi: 10.1021/acs.jproteome.6b00755. Epub 2016 Nov 17. J Proteome Res. 2016. PMID: 27794609 Free PMC article.
-
The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone.Bioorg Med Chem. 2010 Jan 1;18(1):249-66. doi: 10.1016/j.bmc.2009.10.061. Epub 2009 Oct 31. Bioorg Med Chem. 2010. PMID: 19932969 Free PMC article.
-
Synthesis of a versatile metacyclophane macrolactam.Tetrahedron Lett. 2008 Jan 1;49(1):141-144. doi: 10.1016/j.tetlet.2007.10.150. Tetrahedron Lett. 2008. PMID: 19568319 Free PMC article.
-
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.Drugs. 2015 Aug;75(12):1323-34. doi: 10.1007/s40265-015-0440-8. Drugs. 2015. PMID: 26187774 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
